adenovirus infection
Conditions
Interventions
The induction therapy consists of CDV 3 mg/kg/day infused intravenously for 1 hr once a week for the first 3 weeks. The same dose is administered once every 2 weeks after the induction therapy as main
Sponsors
Hematology, Osaka City University, Graduate School of Meicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who had received allogeneic hematopoietic stem cell transplantation (using bone marrow, peripheral blood or cord blood as stem cell source)must be fulfilled at least one of the following. 1) Patients who were diagnosed as adenovirus infection refractory to conservative treatment 2) Patients with adenoviremia who have clinical manifestation
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria are not eligible. 1) Positive for anti-HIV antibody 2) Positive for hepatitis B surface antigen or HBV-DNA 3) Positive for anti-HCV antibody 4) Creatinine clearance lower than 0.1ml/min/kg calculated by the Cockcroft-Gault formula 5) Patients who have coexisting sinusoidal obstruction syndrome 6) Known hypersensitivity to cidofovir 7) Known hypersensitivity to probenecid 8) Patients who are ineligible for this study as judged by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disappearance of signs and symptoms in association with adenovirus infection Elimination of adenovirus from the tissue specimen on which diagnosis of adenovirus infection was made. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of viral load Improvement of clinical symptoms, imaging findings and abnormal laboratory values in association with adenovirus infection. | — |
Countries
Japan
Contacts
Public ContactMika Nakamae
Osaka City University, Graduate School of Medicine Hematology(Clinical research center for hematological malignancies )
Outcome results
None listed